Overview
- The starting 0.25 mg dose now costs ₹2,712 per week and the highest 2.4 mg dose is about ₹16,400 per month, according to company communications to distributors and statements.
- Eli Lilly’s Mounjaro has surged ahead by value, generating roughly ₹100 crore in October sales versus far lower Wegovy revenue, market trackers report.
- Two days earlier, Novo Nordisk named Emcure as exclusive distributor for Poviztra, a second Wegovy brand, to extend semaglutide reach beyond its existing pharmacy network.
- Semaglutide loses patent protection in India in March 2026, a shift expected to open the door to generics and intensify price competition.
- Novo Nordisk says Ozempic has secured CDSCO approval and it plans an Indian launch with initial supplies imported from Denmark.